The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages 351-364

  De Martino, Maria Cristina ^a,b   Van Koetsveld, Peter M ^a   Feelders, Richard A ^a   Sprij Mooij, Diana ^a   Waaijers, Marlijn ^a   Lamberts, Steven W J ^a   De Herder, Wouter W ^a   Colao, Annamaria ^b   Pivonello, Rosario ^b   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; PHOSPHOPROTEIN; RAPAMYCIN; SOMATOMEDIN B; TEMSIROLIMUS;

ADRENAL CORTEX CARCINOMA; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HYDROCORTISONE RELEASE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; HYDROCORTISONE; INSULIN-LIKE GROWTH FACTOR II; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84862673869     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0270     Document Type: Article

References (36)

1. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037. (doi:10.1210/jc.2005-2639)
2. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Maciel CC, Mattos GE, Jorge AA et al. 2008 Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 93 3524-3531. (doi:10.1210/jc.2008-0065)
3. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP et al. 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology 22 909-918. (doi:10.1200/JCO.2004.08.185)
4. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E & Hammer GD 2009 Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 94 204-212. (doi:10.1210/jc.2008-1456)
5. Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, Dumont F, Dechamps F, Caramella C, Chanson P et al. 2011 Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Hormones & Cancer 2 363-371. (doi:10.1007/s12672-011-0094-2)
6. Cantini G, Lombardi A, Piscitelli E, Poli G, Ceni E, Marchiani S, Ercolino T, Galli A, Serio M, Mannelli M et al. 2008 Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Research 2008 904041. (doi:10.1155/2008/904041)
7. De Martino MC, van Koetsveld PM, Pivonello R &Hofland LJ 2010 Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology 92 (Suppl 1) 28-34. (doi:10.1159/000314280)
8. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP & Lalli E 2010 Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Research 70 4666-4675. (doi:10.1158/0008-5472.CAN-09-3970)
9. Easton JB, Kurmasheva RT & Houghton PJ 2006 IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell 9 153-155. (doi:10.1016/j.ccr. 2006.02.027)
10. Fassnacht M, Libe R, Kroiss M & Allolio B 2011 Adrenocortical carcinoma: a clinician's update. Nature Reviews. Endocrinology 7 323-335. (doi:10.1038/nrendo.2010.235)
11. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC & Dimitrov DS 2006 Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Molecular Cancer Therapeutics 5 114-120. (doi:10.1158/1535-7163.MCT-05-0252)
12. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA &Stratton MR 2008 The Catalogue of Somatic Mutations in Cancer (COSMIC). Current Protocols in Human Genetics Chapter 10 Unit 10 11.
13. Franken NA, Rodermond HM, Stap J, Haveman J & van Bree C 2006 Clonogenic assay of cells in vitro. Nature Protocols 1 2315-2319. (doi:10.1038/nprot.2006.339)
14. Guertin DA & Sabatini DM 2007 Defining the role of mTOR in cancer. Cancer Cell 12 9-22. (doi:10.1016/j.ccr.2007.05.008)
15. Hanna SC, Heathcote SA & Kim WY 2008 mTOR pathway in renal cell carcinoma. Expert Review of Anticancer Therapy 8 283-292. (doi:10.1586/14737140. 8.2.283)
16. Hofland LJ, van Koetsveld PM & Lamberts SW 1990 Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. European Journal of Cancer 26 37-44. (doi:10.1016/0277-5379(90)90254-Q)
17. Huang S & Houghton PJ 2002 Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Current Opinion in Investigational Drugs 3 295-304. (Pubitemid 34456089)
18. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 356 2271-2281. (doi:10.1056/NEJMoa066838)
19. Kerstens HM, Robben JC, Poddighe PJ, Melchers WJ, Boonstra H, de Wilde PC, Macville MV & Hanselaar AG 2000 AgarCyto: a novel cell-processing method for multiple molecular diagnostic analyses of the uterine cervix. Journal of Histochemistry and Cytochemistry 48 709-718. (doi:10.1177/002215540004800515)
20. Konings IR, Verweij J, Wiemer EA & Sleijfer S 2009 The applicability of mTOR inhibition in solid tumors. Current Cancer Drug Targets 9 439-450. (doi:10.2174/156800909788166556)
21. Kurmasheva RT, Huang S & Houghton PJ 2006 Predicted mechanisms of resistance to mTOR inhibitors. British Journal of Cancer 95 955-960. (doi:10.1038/sj.bjc.6603353)
22. Libe R & Bertherat J 2005 Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. European Journal of Endocrinology 153 477-487. (doi:10.1530/eje.1.02004)
23. Liu P, Cheng H, Roberts TM & Zhao JJ 2009 Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews. Drug Discovery 8 627-644. (doi:10.1038/nrd2926)
24. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P & Hall MN 2002 Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Molecular Cell 10 457-468. (doi:10.1016/S1097-2765(02)00636-6)
25. Logie A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y & Gicquel C 1999 Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology 23 23-32. (doi:10.1677/jme.0.0230023)
26. LoPiccolo J, Blumenthal GM, Bernstein WB & Dennis PA 2008 Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates 11 32-50. (doi:10.1016/j.drup.2007.11.003)
27. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29 e45. (doi:10.1093/nar/29.9.e45)
28. Rasmussen R 2001 Quantification on the LightCycler. In Rapid Cycle Real-time PCR, Methods and Applications, pp 21-34. Eds S Meuer, C Wittwer & K Nagakawara. Heidelberg: Springer Press.
29. Sabatini AM 2006 Quaternion-based extended Kalman filter for determining orientation by inertial and magnetic sensing. IEEE Transactions on Biomedical Engineering 53 1346-1356. (doi:10.1109/TBME.2006.875664)
30. Sarbassov DD, Guertin DA, Ali SM & Sabatini DM 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 1098-1101. (doi:10.1126/science.1106148)
31. Schmittgen TD & Livak KJ 2008 Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 3 1101-1108. (doi:10.1038/nprot.2008. 73)
32. Volante M, Buttigliero C, Greco E, Berruti A & Papotti M 2008 Pathological and molecular features of adrenocortical carcinoma: an update. Journal of Clinical Pathology 61 787-793. (doi:10.1136/jcp.2007.050625)
33. Wan X & Helman LJ 2007 The biology behind mTOR inhibition in sarcoma. Oncologist 12 1007-1018. (doi:10.1634/theoncologist.12-8-1007)
34. Wan X, Harkavy B, Shen N, Grohar P & Helman LJ 2007 Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26 1932-1940. (doi:10.1038/sj.onc.1209990)
35. Wang T & Rainey WE 2012 Human adrenocortical carcinoma cell lines. Molecular and Cellular Endocrinology 351 58-65. (doi:10.1016/j.mce.2011.08.041)
36. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH & Auernhammer CJ 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 54-60. (doi:10.1159/000100057)